{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:26:36Z","timestamp":1794291996307,"version":"4.9.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF), is commonly used to prevent febrile neutropenia (FN), a potentially life-threatening complication, following myelosuppressive chemotherapy. The FDA label for pegfilgrastim specifies that it should not be administered 14\u2009days before or within 24\u2009h of administration of myelosuppressive chemotherapy, precluding the use of pegfilgrastim in biweekly (Q2W) regimens. The National Comprehensive Cancer Network and the European Organisation for Research and Treatment of Cancer guidelines support the use of prophylactic pegfilgrastim in patients receiving Q2W regimens. The objective of this study was to systematically review evidence from randomized clinical trials (RCTs) and observational studies that describe the effectiveness and safety of prophylactic pegfilgrastim in preventing FN among patients receiving Q2W regimens.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An Ovid MEDLINE, Embase, and Cochrane Library literature search was conducted to evaluate the evidence regarding efficacy, effectiveness, and safety of prophylactic pegfilgrastim versus no prophylactic pegfilgrastim or prophylaxis with other G-CSF in patients who were receiving Q2W chemotherapy regimens with high (&gt;\u200920%) or intermediate (10\u201320%) risk of FN for a non-myeloid malignancy. Studies that addressed absolute or relative risk of FN, grade 1\u20134 neutropenia, all-cause or any hospitalization, dose delays or dose reductions, adverse events, or mortality were included. Studies where the comparator was a Q3W chemotherapy regimen with primary prophylactic pegfilgrastim were also included.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The initial literature search identified 2258 publications. Thirteen publications met the eligibility criteria, including eight retrospective, one prospective, one phase 1 dose escalation study, and three RCTs. In nine of the 13 studies reporting incidence of FN, and in seven of the nine studies reporting incidence of neutropenia, administration of prophylactic pegfilgrastim in patients receiving Q2W regimens resulted in decreased or comparable rates of FN or neutropenia compared with patients receiving filgrastim, no G-CSF, lipefilgrastim or pegfilgrastim in Q3W regimens. In six of the nine studies reporting safety data, lower or comparable safety profiles were observed between pegfilgrastim and comparators.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In a variety of non-myeloid malignancies, administration of prophylactic pegfilgrastim was efficacious in reducing the risk of FN in patients receiving high- or intermediate-risk Q2W regimens, with an acceptable safety profile.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:bold>PROSPERO registration no<\/jats:bold>: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42019155572\">CRD42019155572<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08258-w","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T10:08:37Z","timestamp":1622110117000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7711-8627","authenticated-orcid":false,"given":"Reshma","family":"Mahtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin\u00e9ad M.","family":"Flannery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Schenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad L.","family":"Gawade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,27]]},"reference":[{"issue":"10","key":"8258_CR1","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258\u201366. https:\/\/doi.org\/10.1002\/cncr.21847.","journal-title":"Cancer"},{"issue":"21","key":"8258_CR2","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158\u201367. https:\/\/doi.org\/10.1200\/JCO.2006.08.8823.","journal-title":"J Clin Oncol"},{"issue":"23","key":"8258_CR3","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1002\/cncr.25332","volume":"116","author":"GH Lyman","year":"2010","unstructured":"Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010;116(23):5555\u201363. https:\/\/doi.org\/10.1002\/cncr.25332.","journal-title":"Cancer"},{"issue":"5","key":"8258_CR4","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3892\/etm.2011.312","volume":"2","author":"MB Schilling","year":"2011","unstructured":"Schilling MB, Parks C, Deeter RG. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med. 2011;2(5):859\u201366. https:\/\/doi.org\/10.3892\/etm.2011.312.","journal-title":"Exp Ther Med"},{"key":"8258_CR5","unstructured":"National Comprehensive Cancer Network. National Comprehensive Care Network Clinical Practice Guidelines in Oncology. (NCCN Guidelines\u00ae) Hematopoietic Growth Factors. Version 2.2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdfAccessed Date 28 April 2020."},{"issue":"1","key":"8258_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2010.10.013.","journal-title":"Eur J Cancer"},{"issue":"Suppl 5","key":"8258_CR7","doi-asserted-by":"publisher","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","volume":"21","author":"J Crawford","year":"2010","unstructured":"Crawford J, Caserta C, Roila F, Group EGW. Hematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol. 2010;21(Suppl 5):v248\u201351. https:\/\/doi.org\/10.1093\/annonc\/mdq195.","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"8258_CR8","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):v111\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdw325.","journal-title":"Ann Oncol"},{"issue":"5","key":"8258_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4174\/astr.2018.94.5.223","volume":"94","author":"J Lee","year":"2018","unstructured":"Lee J, Lee JE, Kim Z, Han SW, Hur SM, Kim SY, et al. Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy. Ann Surg Treat Res. 2018;94(5):223\u20138. https:\/\/doi.org\/10.4174\/astr.2018.94.5.223.","journal-title":"Ann Surg Treat Res"},{"issue":"12","key":"8258_CR10","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1080\/03007995.2017.1386858","volume":"33","author":"D Weycker","year":"2017","unstructured":"Weycker D, Bensink M, Lonshteyn A, Doroff R, Chandler D. Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015. Curr Med Res Opin. 2017;33(12):2107\u201313. https:\/\/doi.org\/10.1080\/03007995.2017.1386858.","journal-title":"Curr Med Res Opin"},{"issue":"18","key":"8258_CR11","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1161\/CIR.0000000000000128","volume":"130","author":"DK Arnett","year":"2014","unstructured":"Arnett DK, Goodman RA, Halperin JL, Anderson JL, Parekh AK, Zoghbi WA. AHA\/ACC\/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and US Department of Health and Human Services. Circulation. 2014;130(18):1662\u20137. https:\/\/doi.org\/10.1161\/CIR.0000000000000128.","journal-title":"Circulation"},{"issue":"3","key":"8258_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1200\/JOP.091094","volume":"6","author":"HA Burris","year":"2010","unstructured":"Burris HA, Belani CP, Kaufman PA, Gordon AN, Schwartzberg LS, Paroly WS, et al. Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast Cancer, non-small-cell lung Cancer, ovarian Cancer, and non-Hodgkin\u2019s lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract. 2010;6(3):133\u201340. https:\/\/doi.org\/10.1200\/JOP.091094.","journal-title":"J Oncol Pract"},{"issue":"4","key":"8258_CR13","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1200\/JCO.1996.14.4.1224","volume":"14","author":"EK Rowinsky","year":"1996","unstructured":"Rowinsky EK, Grochow LB, Sartorius SE, Bowling MK, Kaufmann SH, Peereboom D, et al. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol. 1996;14(4):1224\u201335. https:\/\/doi.org\/10.1200\/JCO.1996.14.4.1224.","journal-title":"J Clin Oncol"},{"issue":"15","key":"8258_CR14","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/jnci\/84.15.1201","volume":"84","author":"NJ Meropol","year":"1992","unstructured":"Meropol NJ, Miller LL, Korn EL, Braitman LE, MacDermott ML, Schuchter LM. Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst. 1992;84(15):1201\u20133. https:\/\/doi.org\/10.1093\/jnci\/84.15.1201.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"8258_CR15","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke Statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56\u2013e528. https:\/\/doi.org\/10.1161\/CIR.0000000000000659.","journal-title":"Circulation"},{"key":"8258_CR16","unstructured":"National Institute for Health Research. PROSPERO Internaton prospective register of systematic reviews. https:\/\/www.crd.york.ac.uk\/prospero\/"},{"issue":"oct18 2","key":"8258_CR17","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"key":"8258_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jclinepi.2018.01.012","volume":"111","author":"HJ Schunemann","year":"2019","unstructured":"Schunemann HJ, Cuello C, Akl EA, Mustafa RA, Meerpohl JJ, Thayer K, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol. 2019;111:105\u201314. https:\/\/doi.org\/10.1016\/j.jclinepi.2018.01.012.","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"8258_CR19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/COC.0000000000000141","volume":"37","author":"L Balducci","year":"2014","unstructured":"Balducci L, Mo M, Abella E, Saven A. Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim. Am J Clin Oncol. 2014;37(6):603\u201310. https:\/\/doi.org\/10.1097\/COC.0000000000000141.","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"8258_CR20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/bjh.13358","volume":"169","author":"V Bozzoli","year":"2015","unstructured":"Bozzoli V, Tisi MC, Maiolo E, Alma E, Bellesi S, D'Alo F, et al. Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma. Br J Haematol. 2015;169(6):787\u201394. https:\/\/doi.org\/10.1111\/bjh.13358.","journal-title":"Br J Haematol"},{"issue":"10","key":"8258_CR21","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1177\/1060028017714554","volume":"51","author":"KN Donkor","year":"2017","unstructured":"Donkor KN, Selim JH, Waworuntu A, Lewis K. Safety and efficacy of Pegfilgrastim when given less than 14 days before the next chemotherapy cycle: review of every 14-day chemotherapy regimen containing 5-FU continuous infusion. Ann Pharmacother. 2017;51(10):840\u20137. https:\/\/doi.org\/10.1177\/1060028017714554.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"8258_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000313526","volume":"56","author":"KH Dragnev","year":"2010","unstructured":"Dragnev KH, Hardin SB, Pipas JM, Davis TH, Rigas JR. A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors. Chemotherapy. 2010;56(2):135\u201341. https:\/\/doi.org\/10.1159\/000313526.","journal-title":"Chemotherapy"},{"issue":"2","key":"8258_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3816\/CCC.2010.n.013","volume":"9","author":"JR Hecht","year":"2010","unstructured":"Hecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, et al. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer. 2010;9(2):95\u2013101. https:\/\/doi.org\/10.3816\/CCC.2010.n.013.","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"8258_CR24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/COC.0b013e3181f94716","volume":"34","author":"D Hendler","year":"2011","unstructured":"Hendler D, Rizel S, Yerushalmi R, Neiman V, Bonilla L, Braunstein R, et al. Different schedules of granulocyte growth factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy: a prospective nonrandomized study. Am J Clin Oncol. 2011;34(6):619\u201324. https:\/\/doi.org\/10.1097\/COC.0b013e3181f94716.","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"8258_CR25","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s00520-014-2555-y","volume":"23","author":"G Kourlaba","year":"2015","unstructured":"Kourlaba G, Dimopoulos MA, Pectasides D, Skarlos DV, Gogas H, Pentheroudakis G, et al. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Support Care Cancer. 2015;23(7):2045\u201351. https:\/\/doi.org\/10.1007\/s00520-014-2555-y.","journal-title":"Support Care Cancer"},{"key":"8258_CR26","unstructured":"Kurbacher C, Kurbacher A, Monreal K, Schweitzer C, Sperling S, Kolberg G, Kurbacher J: Primary prophylaxis of febrile neutropenia in female patients receiving dose-dense biweekly chemotherapy in the clinical routine using long-acting granulocyte colony-stimulating factors is safe and effective. In: Oncology Research and Treatment Conference: 32 Deutscher Krebskongress, DKK 2016 Berlin, Germany Conference Publication: (varpagings) 2016;39(Suppl 1):152. 2016."},{"issue":"9","key":"8258_CR27","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1080\/10428190600632832","volume":"47","author":"SW Lane","year":"2006","unstructured":"Lane SW, Crawford J, Kenealy M, Cull G, Seymour JF, Prince HM, et al. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (hyper-CVAD) for lymphoid malignancy. Leuk Lymphoma. 2006;47(9):1813\u20137. https:\/\/doi.org\/10.1080\/10428190600632832.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"8258_CR28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.clml.2012.06.004","volume":"12","author":"P Lugtenburg","year":"2012","unstructured":"Lugtenburg P, Silvestre AS, Rossi FG, Noens L, Krall W, Bendall K, et al. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. Clin Lymphoma Myeloma Leuk. 2012;12(5):297\u2013305. https:\/\/doi.org\/10.1016\/j.clml.2012.06.004.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"8258_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000321545","volume":"125","author":"JH Ng","year":"2011","unstructured":"Ng JH, Ang XY, Tan SH, Tao M, Lim ST, Chan A. Breakthrough febrile neutropenia and associated complications in non-Hodgkin's lymphoma patients receiving pegfilgrastim. Acta Haematol. 2011;125(3):107\u201314. https:\/\/doi.org\/10.1159\/000321545.","journal-title":"Acta Haematol"},{"issue":"2","key":"8258_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clcc.2016.08.008","volume":"16","author":"T Pinter","year":"2017","unstructured":"Pinter T, Klippel Z, Cesas A, Croitoru A, Decaestecker J, Gibbs P, et al. A phase III, randomized, double-blind, placebo-controlled trial of Pegfilgrastim in patients receiving first-line FOLFOX\/Bevacizumab or FOLFIRI\/Bevacizumab for locally advanced or metastatic colorectal Cancer: final results of the Pegfilgrastim and anti-VEGF evaluation study (PAVES). Clin Colorectal Cancer. 2017;16(2):103\u201314 e103. https:\/\/doi.org\/10.1016\/j.clcc.2016.08.008.","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"8258_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000229504","volume":"77","author":"DV Skarlos","year":"2009","unstructured":"Skarlos DV, Timotheadou E, Galani E, Samantas E, Grimani I, Lianos E, et al. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic cooperative oncology group. Oncology. 2009;77(2):107\u201312. https:\/\/doi.org\/10.1159\/000229504.","journal-title":"Oncology"},{"issue":"4","key":"8258_CR32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1136\/ewjm.172.4.248","volume":"172","author":"HG Munshi","year":"2000","unstructured":"Munshi HG, Montgomery RB. Severe neutropenia: a diagnostic approach. West J Med. 2000;172(4):248\u201352. https:\/\/doi.org\/10.1136\/ewjm.172.4.248.","journal-title":"West J Med"},{"issue":"6","key":"8258_CR33","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1200\/JOP.2016.019588","volume":"13","author":"E Tai","year":"2017","unstructured":"Tai E, Guy GP, Dunbar A, Richardson LC. Cost of Cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract. 2017;13(6):e552\u201361. https:\/\/doi.org\/10.1200\/JOP.2016.019588.","journal-title":"J Oncol Pract"},{"issue":"8 Pt 2","key":"8258_CR34","doi-asserted-by":"publisher","first-page":"15S","DOI":"10.1592\/phco.23.9.15S.32889","volume":"23","author":"J Crawford","year":"2003","unstructured":"Crawford J. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy. 2003;23(8 Pt 2):15S\u20139S. https:\/\/doi.org\/10.1592\/phco.23.9.15S.32889.","journal-title":"Pharmacotherapy"},{"issue":"33","key":"8258_CR35","doi-asserted-by":"publisher","first-page":"8340","DOI":"10.1200\/JCO.2005.02.8621","volume":"23","author":"HJ Burstein","year":"2005","unstructured":"Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005;23(33):8340\u20137. https:\/\/doi.org\/10.1200\/JCO.2005.02.8621.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8258_CR36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/sj.bjc.6604862","volume":"100","author":"RL Jones","year":"2009","unstructured":"Jones RL, Walsh G, Ashley S, Chua S, Agarwal R, O'Brien M, et al. A randomised pilot phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br J Cancer. 2009;100(2):305\u201310. https:\/\/doi.org\/10.1038\/sj.bjc.6604862.","journal-title":"Br J Cancer"},{"issue":"5","key":"8258_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00408-005-2594-8","volume":"184","author":"R Pirker","year":"2006","unstructured":"Pirker R, Ulsperger E, Messner J, Aigner K, Forstner B, Bacon P, et al. Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. Lung. 2006;184(5):279\u201385. https:\/\/doi.org\/10.1007\/s00408-005-2594-8.","journal-title":"Lung"},{"issue":"30","key":"8258_CR38","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1200\/JCO.2011.34.8508","volume":"29","author":"T Watanabe","year":"2011","unstructured":"Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, Maseki N, et al. Phase II\/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. J Clin Oncol. 2011;29(30):3990\u20138. https:\/\/doi.org\/10.1200\/JCO.2011.34.8508.","journal-title":"J Clin Oncol"},{"issue":"8","key":"8258_CR39","doi-asserted-by":"publisher","first-page":"560","DOI":"10.7326\/0003-4819-159-8-201310150-00709","volume":"159","author":"MA Hernan","year":"2013","unstructured":"Hernan MA, Hernandez-Diaz S, Robins JM. Randomized trials analyzed as observational studies. Ann Intern Med. 2013;159(8):560\u20132. https:\/\/doi.org\/10.7326\/0003-4819-159-8-201310150-00709.","journal-title":"Ann Intern Med"},{"issue":"19","key":"8258_CR40","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1002\/sim.1296","volume":"21","author":"SJ Pocock","year":"2002","unstructured":"Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med. 2002;21(19):2917\u201330. https:\/\/doi.org\/10.1002\/sim.1296.","journal-title":"Stat Med"},{"issue":"4","key":"8258_CR41","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00280-016-2970-5","volume":"77","author":"Y Li","year":"2016","unstructured":"Li Y, Klippel Z, Shih X, Wang H, Reiner M, Page JH. Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy. Cancer Chemother Pharmacol. 2016;77(4):703\u201312. https:\/\/doi.org\/10.1007\/s00280-016-2970-5.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"8258_CR42","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1080\/03007995.2018.1495621","volume":"34","author":"D Weycker","year":"2018","unstructured":"Weycker D, Hanau A, Lonshteyn A, Bowers C, Bensink M, Garawin T, et al. Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged >\/=65 years: a retrospective evaluation using Medicare claims. Curr Med Res Opin. 2018;34(9):1705\u201311. https:\/\/doi.org\/10.1080\/03007995.2018.1495621.","journal-title":"Curr Med Res Opin"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08258-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08258-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08258-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T10:08:56Z","timestamp":1622110136000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08258-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,27]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8258"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08258-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,27]]},"assertion":[{"value":"11 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TL, JS, and PLG are employees of and hold stock in Amgen, Inc.; SMF is an employee of Oxford PharmaGenesis and Oxford PharmaGenesis has received research funding from Amgen, Inc. RM has received fees as a consultant\/advisor for Agendia, Amgen, AstraZeneca, Biotheranostics, Daiichi, Esai, Immunomedics, Lilly, Novartis, Pfizer, Puma, Seattle Genetics and contracted research for Genentech; JC has received grants\/research support from AstraZeneca, Genentech and Helsinn, consultant fees from Amgen, AstraZeneca, Coherus Biosciences, Enzychem Lifesciences, G1 Therapeutics, GlaxoSmithKline, Merck, Pfizer and Spectrum, and is a DSMB Member for Beyond Spring, G1 Therapeutics, Merrimack, Mylan and Roche.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"621"}}